224 References

REFERENCES

1. Alexander S, Juergen S, Bodmeier R. Gastroretentive drug delivery systems.

Expert Opin. Drug Deliv. 3(2), 2006, 217-233.

2. Hirtz J. The GIT absorption of drugs in man: A review of current concepts and

methods of investigation. Br J Clin Pharmacol. 19, 1985, 77S-83S.

3. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system

for oral delivery to the gastrointestinal tract. Adv Drug Del Rev. 34, 1998, 191-

219.

4. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel

controlled-release system for gastric retention. Pharm Res. 14, 1997, 815-819.

5. Rednick AB, Tucker SJ. Sustained release bolus for animal husbandry. US

patent 3 507 952. April 22, 1970.

6. Urguhart J, Theeuwes F. Drug delivery system comprising a reservoir

containing a plurality of tiny pills. US patent 4 434 153. February 28, 1994.

7. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P.

Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy.

J Control Release. 58, 1999, 195-205.

8. Groning R, Heun G. Dosage forms with controlled gastrointestinal passage—

studies on the absorption of nitrofurantion. Int J Pharm. 56, 1989, 111-116.

9. Standley S. Davis. Formulation strategies for absorption window. DDT. 10(4),

2005, 249-257.

10. Hoffman A and Strepensky D. Pharmacodynamic aspects of modes of drug

administration for optimization of drug therapy, Crit Rev Ther Drug Carrier

Syst, 16, 1999, 571-639.

225 References

11. Hejazi R and Amiji M. Stomach specific anti H.pylori therapy. I: preparation

and characterization of tetracycline of a floating multiple-unit capsule, a high-

density loaded chitosan microspheres, Int J Pharm, 235, 2002, 87-94.

12. Dave BS, Amin AF and Patel M. Gastroretentive drug delivery system of

Ranitidine HCl formulation and In vitro evaluation. AAPS Pharm Sci Tech, 5,

2004, 1-10.

13. Sawicki W. Pharmacokinetics of verapamil and nor verapamil from controlled

release floating pellets in humans. Eur J Pharm Biopharm, 53, 2002, 29-35.

14. Davis SS et al., Transit of pharmaceutical dosage forms through the small

intestine, Gut 27, 1986, 886-892.

15. Desai S, A Novel Floating Controlled Release Drug Delivery System Based on a

Dried Gel Matrix Network, [master’s thesis]. 1984 Jamaica, NY, St John’s

University.

16. Vantrappen G R, Peeters T L, Janssens J. The secretory component of

interdigestive migratory motor complex in man, Scand J Gastroenterol. 14,

1979, 663-667.

17. Pooja Mathur, Kamal Saroha, et al., Floating drug delivery system: An

innovative acceptable approach in gastroretentive drug delivery, Archives of

Applied Science Research, 2 (2), 2010, 257-270.

18. Desai S, Bolton SA. A floating controlled release drug delivery system: In vitro-

In vivo evaluation, Pharm Res, 10, 1993, 1321-1325.

19. Wilson CG and Washington N. Review: Physiological Pharmaceutics: Barriers

to Drug Absorption, 2nd

edn. Chichester: Ellis Horwood, 2001, 47.

226 References

20. Rubinstein A, Gruber VH, Robinson JR. In oral sustained release formulations:

Design and evaluation, edited by A Yacobi and E Halperin-Walega (Pergamon

Press, New York) 1988, 125-126.

21. SH. Shaha, JK. Patel, K.Pundarikakshdu, N.V. Patel. An overview of a gastric-

retentive floating drug delivery system, Asian Journal of Pharmaceutical

Sciences 4(1), 2009, 65-80.

22. Park HM, Chernish SM, Rosenek BD, et al. Gastric emptying of enteric-coated

tablets. Dig Dis Sci 29, 1984, 207-12.

23. Meyer JH, Dressman J, Fink A and Amidon G. Effect of size and density on

canine gastric emptying of nondigestible solids. Gastroent. 89(4), 1985, 805-13.

24. Jose Gutierrez-Rocca, Hossein Omidian and Khalid Shah, Progress in

Gastroretentive Drug Delivery Systems, Pharmatech, 2003, 152.

25. A.K. Hilton, P.B. Daisy, In vitro and In vivo evaluation of an oral sustained-

release floating dosage form of amoxycillin trihydrate, Int. J. Pharm. 86, 1992

79–88.

26. P.R. Sheth, J.L. Tossounian, Sustained release pharmaceutical capsules, US

Patent 4, November 21, 1978, 126, 672.

27. Harrigan RM. Drug delivery device for preventing contact of undissolved drug

with the stomach lining, US Patent 4, October 25, 1977, 055, 178.

28. Whitehead L, Fell JT, Collett JH. Development of a gastroretentive dosage

form. Eur. J. Pharm. Sci. 4 (Suppl.), 1996, S182.

29. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres for

use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci.

81, 1992, 135-140.

227 References

30. Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract, In Domb

AJ (Ed.) Polymeric site specific pharmacotherapy, Wiley, Chichester, 1994,

282-283.

31. Stockwell AF, Davis SS, walker SE. In vitro evaluation of alginate gel system as

sustained release drug delivery system. J Control Release. 3, 1986, 167-175.

32. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel

gastroretentive dosage form: evaluation of gastroretentivity and its effect on

riboflavin absorption in dogs. Pharm. Res. 19, 2002, 1516-1523.

33. Moes AJ. Gastroretentive Dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 10,

1993, 143-195.

34. Bechgaard H, Ladefoged K. Distribution of pellets in the gastrointestinal tract.

The influence on transit time exerted by the density or diameter of pellets. J.

Pharm. Pharmacol. 30, 1978, 690-692.

35. Wong P S L. Dong L C Edgren D E, Theeuwes RGardner P I. Jao F & Wan J J.

Prolonged release active agent dosage form adapted for gastric retention. US Pat

6120803, September 19, 2000.

36. El-Kamel A H, Sokar M S, Gamal S S A & Naggar V R. Preparation and

evaluation of ketoproten floating oral delivery system, hit J Pharm, 220, 2001,

13-21.

37. Moes A, Oth M, Franz M, Timmcrmans J. The bilayer floating capsule: a

stomach-directed drug delivery system for misoprostol, Pharm Res, 9, 1992,

298-302.

38. Kolter et al. Active ingredient containing floating forms comprising polyvinyl

acetate and polyvinyl pyrrolidone, their use and production. US pat 6, 635, 279.

228 References

39. Watanabe K, Machida Y, Takayama K, Iwata M & Nagai T. Preparation and

evaluation of intragastric floating tablet having pH independent buoyancy and

sustained release property, Arch Pract Pharm, 53, 1993, 1-7.

40. Umamaheshwari R B, Jain S & Jain N K. A new approach in gastroretentive

drug delivery system using cholestyramine, Drug Deliv, 10, 2003, 151 -160.

41. Timmermans J, Moes AJ. How well does floating dosage forms float. Int J

Pharm. 62, 1990, 207-16.

42. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. Floating dosage

forms: An In vivo study demonstrating prolonged gastric retention. J Control

Release. 55, 1998, 3-12.

43. Mojaverian P, Vlasses PH, Kellner PE, Rocci Jr ML. Effects of gender, posture,

and age on gastric residence time of an indigestible solid: Pharmaceutical

considerations. Pharm. Res. 10, 1988, 639-44.

44. Gansbeke BV, Timmermans J, Schoutens A, Moes AJ. Intragastric positioning

of two concurrently ingested pharmaceutical matrix dosage forms. Nucl Med

Biol. 18, 1991, 711-18.

45. Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention

capabilities of floating matrix capsules: New data for reconsidering the

controversy. J Pharm Sci. 83, 1994, 18-24.

46. Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating

dosage forms containing salbutamol sulphate. Pharmazie. 45, 1990, 268-270.

47. Hetal N Kikani, A Thesis on, Floating Drug Delivery System, The North

Gujarat University, Patan, 2001, 11-12.

229 References

48. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral

controlled drug delivery via gastric retention. J Control Release, 63, 2000, 235-

259.

49. Fell J T, Whitehead L, Collet H. Prolonged gastric retention using floating

dosage forms, Pharm Technol. 24(3), 2000, 82-90.

50. Menon A, Ritschel WA , Sakr A. Development and evaluation of a monolithic

floating dosage form for furosemide. J Pharm Sci. 83, 1994, 239-245.

51. Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel Levodopa

gastroretentive dosage form: In vivo evaluation in dogs. J. Controlled release.

88, 2003, 117-126.

52. Amnon Hoffman, David Stepensky, Eran Lavy, et al., Pharmacokinetic and

pharmacodynamic aspects of gastroretentive dosage forms, International Journal

of Pharmaceutics 277, 2004, 141–153.

53. Hoffman A. Pharmacodynamic aspects of sustained release preparation. Adv.

Drug Deliv. Rev. 33, 1998, 185-199.

54. R Garg and GD Gupta, Progress in Controlled Gastroretentive Delivery

Systems, Tropical Journal of Pharmaceutical Research, 7(3), 2008, 1055-1066.

55. Bakker A J, De Winter L M, Fabiano S, Inventors; Oral sustained release

formulation of tedisamil with gastric retention properties. US Patent Appl

2006003003. Jan 2006.

56. British National Formulary. 52 ed. London: British Medical Association and

Royal Pharmaceutical Society of Great Britain, 2006.

57. Drug profile of Famotidine from "http://en.wikipedia.org/wiki/Famotidine"

[Accessed: 05/04/2008].

230 References

58. Debas H. T, Mullholland M. W. New horizons in the pharmacologic

management of peptic ulceration. Am J Surgery. 151(3), 1986, 422-430.

59. Goodman and Gilmans – The pharmacological basis of therapeutics. 11th ed.,

McGraw Hill medical publishing division: New York, 2006, 1866.

60. Murakami H, Sun-Wada G.H, Matsumoto M, Nishi T, Wada Y, Futai M.

Human histamine H2 receptor gene: multiple transcription initiation and tissue-

specific expression. FEBS Lett. 451(3), 1999, 327-31.

61. Raymond C Rowe, Paul J Sheskey, Sian C Owen, Handbook of Pharmaceutical

Excipients. 5th ed., Pharmaceutical Press: London; 2006. 111-115, 346-349,

120-123, 315-317, 821-823.

62. Raymond C Rowe, Paul J Sheskey, Sian C Owen, Handbook of Pharmaceutical

Excipients. 5th ed., Pharmaceutical Press: London; 2006. 159-162.

63. A. Streubel, J. Siepmann and R. Bodmeier. Floating matrix tablets based on low

density foam powder: effects of formulation and processing parameters on drug

release, European Journal of Pharmaceutical Sciences, 18(1), 2003, 37-45.

64. Mirchandani HL, Chien YW, Bruce PD, Senshang L, Shoufeng L. Effect of

HPMC and carbopol on the release and floating properties of gastric floating

drug delivery system using factorial design. Int J Pharm., 253, 2003, 13-22.

65. Ozdemir N, Ordu S, Ozkan Y, Studies of floating dosage forms of furosemide:

In vitro and In vivo evaluations of bilayer tablet formulations, Drug Dev Ind

Pharm. 26(8), 2000, 857-66.

66. Sheth P R & Tossounian J. The hydrodynamically balanced system (HBSE): A

novel drug delivery system for oral use, Drug Dev bid Pharrn, 10, 1984, 313-

339.

231 References

67. Ingani H M, Timmermans J & Moes A J. Conception and In vivo investigation

of peroral sustained release floating dosage forms with enhanced gastrointestinal

transit, Int J Pharm. 35, 1987, 157-164.

68. Agyilirah GA, Green M, Ducret R. Evaluation of the gastric retention properties

of a cross-linked polymer coated tablet versus those of a non-disintegrating

tablets. Int J Pharm., 75, 1991, 241-247.

69. Hilton, A. K. Deasy, P. B. In vitro and In vivo evaluation of an oral sustained

Release floating dosage form of amoxicillin trihydrate. Int. J. Pharm. 86, 1992,

79‐88.

70. Subhash Desai, Sanford Bolton. A Floating Controlled-Release Drug Delivery

System: In vitro-In vivo Evaluation, Pharmaceutical Research, 10(9), 1993,

1321-1325.

71. A. Menon, W. Ritschel and A. Sakr, Development and evaluation of a

monolithic floating dosage form for furosemide. J. Pharm. Sci. 83, 1994, 239–

245.

72. J. Timmermans and A. J. Moes. Factors controlling the buoyancy and gastric

retention capabilities of floating matrix capsules: new data for reconsidering the

controversy, J. Pharm. Sci., 83, 1994, 8–24.

73. Libo Yang a, Jamshid Eshraghi b and Reza Fassihi. Zero-order release kinetics

from a self-correcting floatable asymmetric configuration drug delivery system.

J. Pharm. Sci. 85, 1996, 170–173.

74. Deshpande A.A., Shah N.H., Rhodes C.T., Malick. W. Development of a novel

controlled-release system for gastric retention. Pharm. Res. 14, 1997, 815-819.

75. Chen, G.L. Hao, W.H. In vitro performance of floating sustained-release capsule

of verapamil, Drug Dev. Ind. Pharm. 24, 1998, 1067–1072.

232 References

76. I. Krogel, R. Bodmeier. Floating or pulsatile drug delivery systems based on

coated effervescent cores, Int. J. Pharm. 187 (2), 1999, 175-184.

77. Wei Z, Yu Z, Bi D. Design and evaluation of a two-layer floating tablet for

gastric retention using cisapride as a model drug. Drug Dev Ind Pharm, 27,

2001, 469-74.

78. Rosa M, Zia H, Rhodes T. Dosing and testing In vitro of a bioadhesive and

floating drug delivery system for oral application, Int J Pharm 105, 1994, 65-70.

79. Franz M R, Oth M P, Sustained release, bilayer buoyant dosage form, US Pal 5,

August 3, 1993, 232, 704.

80. Dennis A, Timminis P, Lel K. Buoyant controlled release powder formulation.

US patent 5 December 8, 1992, 169, 638.

81. Mitra S B, Sustained release oral medicinal delivery device, US Pat 4, May 29,

1984, 451.

82. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery

systems using polycarbonate microspheres capable of floating on the gastric

fluids. J Pharm Pharmacol. 45, 1993, 21-24.

83. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage

system. I: Preparation and In vitro evaluation of floating and sustained-release

kinetics. J Pharm Sci. 80, 1991, 1062-1066.

84. Atyabi F, Sharma HL, Mohammed HAH, Fell JT. In vivo evaluation of a novel

gastro retentive formulation based on ion exchange resins. J Control Release.

42, 1996, 105-113.

85. Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage

system. II: In vivo evaluation of floating and sustained-release characteristics

233 References

with para amino benzoic acid and isosorbide di nitrate as model drugs. J Pharm

Sci. 80, 1991, 1153-1156.

86. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith A. In vivo study

demonstrating prolonged gastric retention. J Control Release. 55, 1998, 3-12.

87. Iannuccelli, V., Coppi, G., Sansone, R., Ferolla, G. Air compartment multiple-

unit system for prolonged gastric residence.Part II. In vivo evaluation. Int J

Pharm, 174, 1998, 55-62.

88. Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Preparation of multiple unit

hollow microspheres (microballoons) with acrylic resins containing tranilast and

their drug release characteristics (In vivo). J Control Release. 16, 1991, 279-290.

89. El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation

of ketoprofen floating oral drug delivery system. Int J Pharm. 220, 2001, 13-21.

90. Nakamichi K, Yasuura H, Fukui H, Oka M, Izumi S. Evaluation of a floating

dosage form of nicardipine hydrochloride and hydroxypropyl methylcellulose

acetate succinate prepared using a twin-screw extruder, Int J Pharm. May 7

218(1-2), 2001, 103-12.

91. Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process

conditions on casein gelatin beads floating properties. Int J Pharm. 198, 2000,

157-165.

92. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage

form based on alginates. Int J Pharm. 210, 2000, 45-49.

93. Yasunori Sato, Yoshiaki Kawashima, Hirofumi Takeuchi, Hiromitsu

Yamamoto. In vitro evaluation of floating and drug releasing behaviour of

hollow microspheres (micro balloons) prepared by emulsion solvent diffusion

234 References

method. European journal of pharmaceutics and biopharmaceutics, 57, 2004,

235– 243.

94. Timmermans J, Andre JM. Factors controlling the buoyancy and gastric

retention capabilities of floating matrix capsules: new data for reconsidering the

controversy. J Pharm Sci. 83, 1994, 18-24.

95. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for

floating drug delivery: effects of CO2 gas forming agents. Int J Pharm. 239,

2002, 81-91.

96. Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation

variables on the floating properties of gastric floating drug delivery system.

Drug Dev Ind Pharm. 28, 2002, 783-793.

97. Penners G, Lustig K, Jorg PVG. Expandable pharmaceutical forms. US patent 5

July 29, 1997, 651, 985.

98. Fassihi R, Yang L. Controlled release drug delivery systems. US patent 5 July

21, 1998, 783, 212.

99. Talwar N, Sen H, Staniforth JN. Orally administered controlled drug delivery

system providing temporal and spatial control. US patent 6 July 17, 2001, 261

601.

100. Baumgartner S, Kristel J, Vreer F, Vodopivec P, Zorko B. Optimization of

floating matrix tablets and evaluation of their gastric residence time. Int J

Pharm. 195, 2000, 125-135.

101. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and

release kinetics. Drug Dev Ind Pharm. 26, 2000, 965-969.

235 References

102. Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M. Expandable

gastroretentive therapeutic system with controlled active substance release in

gastrointestinal tract. US patent 6 September 18, 2001, 290, 989.

103. Illum L, Ping H. Gastroretentive controlled release microspheres for improved

drug delivery. US patent 6 March 27, 2001, 197, 207.

104. Ushomaru K, Nakachimi K, Saito H. Pharmaceutical preparations and a method

of manufacturing them. US patent 4. October 27, 1987, 702, 918.

105. Bolton S, Desai S. Floating sustained release therapeutic compositions. US

patent 4. March 21, 1989, 179, 814.

106. Spickett RGW, Vidal JLF, Escoi JC. Antacid preparation having prolonged

gastric residence. US patent 5. February 22, 1993, 288,506.

107. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained

release tablet capable of floating on gastric fluids with prolonged gastric resident

time. Yao Xue Xue Bao. 32, 1997, 786-790.

108. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of

ranitidine hydrochloride: formulation and In vitro evaluation. AAPS Pharm Sci

Tech. 5, 2004, E34.

109. Reddy L, Murthy R. Floating dosage systems in drug delivery. Crit Rev Ther

Drug Carrier Syst. 19, 2002, 553-585.

110. Mahesh Chavanpatil, , Paras Jain, Sachin Chaudhari, Rajesh Shear and Pradeep

Vavia, Development of sustained release gastroretentive drug delivery system

for ofloxacin: In vitro and In vivo evaluation, International Journal of

Pharmaceutics, 304 (1-2), 2005, 178-184.

236 References

111. Wong PSL, Dong LC, Edgren DE, Theeuwes F. Prolonged release active agent

dosage form adapted for gastric retention. US patent 6. September 19, 2000,

120, 803.

112. Brijesh S Dave, Avani Amin F. Gastro retentive Drug Delivery System of

Ranitidine Hydrochloride: Formulation and In vitro Evaluation. AAPS Pharm

Sci Tech. 5(2), 2004, 34-40.

113. Dumpeti Janardhan, Meka Lingam. Formulation and In vitro Evaluation of

Gastro retentive Drug Delivery System for Ranitidine Hydrochloride.

International Journal of Pharmaceutical Sciences and Nanotechnology. 1(3),

2008, 272-232.

114. Alagusundaram M., Chengaiah B. Formulation and evaluation of mucoadhesive

buccal films of Ranitidine HCl. Int J Pharma Tech Res. 1(3), 2009, 557-563.

115. Dinesh Dhamecha, Amit A Rathi. Development and In vitro Evaluation of Oral

Floating Matrix Tablet Formulation of Ranitidine Hydrochloride. Research J.

Pharma. Dosage Forms and Tech. 1(1), 2009, 41-44.

116. Chavda H, Patel C. Chitosan superporous hydrogel composite-based floating

drug delivery system: A newer formulation approach. J Pharm Bioall Sci 2,

2010, 124-31.

117. Jaimini M, Rana A.C. Formulation and Evaluation of Famotidine Floating

Tablets. Current Drug Delivery. 4, 2007, 51-55.

118. Monica RP Rao, Girish S Sonar, Rachana R Mandsaurwale, Swapnila D

Vanshiv, Evaluation of effervescent floating matrix tablet formulations of

salbutamol sulfate using full factorial design, Asian Journal of Pharmaceutics,

3(1), 2009, 43-49.

237 References

119. Sauzet C, Claeys-Bruno M, Nicolas M, Kister J, Piccerelle P, Prinderre P. An

innovative floating gastro retentive dosage system: formulation and In vitro

evaluation, Int J Pharm. Aug 13;378(1-2), 2009, 23-29.

120. Ajit Kulkarni, Manish Bhatia. Development and evaluation of regioselective

bilayer floating floating tablets of Atenolol and Lovastatin, Iranian Journal of

Pharmaceutical Research, 8 (1), 2009, 15-25.

121. Ramesh bomma et al. Development and evaluation of gastroretentive

norfloxacin floating tablets, Acta Pharm. 59, 2009, 211–221.

122. Rajeev Garg and GD Gupta. Gastroretentive Floating Microspheres of

Silymarin: Preparation and In vitro Evaluation, Tropical Journal of

Pharmaceutical Research, February 9 (1), 2010, 59-66.

123. Ferdous Khan, Md. Et al. Preparation and In vitro Evaluation of Theophylline

Loaded Gastroretentive Floating Tablets of METHOCEL K4M, Dhaka Univ. J.

Pharm. Sci. 7(1), 2008, 65-70.

124. Shailesh T. Prajapati, Laxmanbhai D. Patel, Dasharath M. Patel, Gastric floating

matrix tablets: Design and optimization using combination of polymers, Acta

Pharm. 58, 2008, 221–229.

125. Goole J, Vanderbist F, Aruighi K. Development and evaluation of new multiple-

unit levodopa sustained-release floating dosage forms. Int J Pharm 334, 2007,

35-41.

126. Patel DM, Patel NM, Pandya NN, Jogani PD. Formulation and optimization of

carbamazepine floating tablets. Indian J Pharm Sci 69, 2007, 763-767.

127. Girish S. Sonar, Devendra K. Jain, Dhananjay M. More. Preparation and In vitro

evaluation of bilayer and floating bioadhesive tablets of rosiglitazone maleate,

Asian Journal of Pharmaceutical Sciences 2 (4), 2007, 161-169.

238 References

128. Jain SK, Agrawal GP, Jain NK. Evaluation of Porous Carrier-based Floating

Orlistat Microspheres for Gastric Delivery. AAPS PharmSciTech. 7(4), 2006,

90.

129. Gambhire MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR. Development

and In vitro Evaluation of an Oral Floating Matrix Tablet Formulation of

Diltiazem Hydrochloride. AAPS PharmSciTech. 8(3), 2007, 73.

130. Ziyaur Rahman, Design and evaluation of bilayer floating tablets of captopril,

Acta Pharm. 56, 2006, 49–57.

131. Jaleh Varshosaz, N Tavakoli, F Roozbahani, Formulation and In vitro

Characterization of Ciprofloxacin Floating and Bioadhesive Extended-Release

Tablets, Drug Delivery 13:44, 277-285.

132. Xiaoqiang Xu, Minije S, Feng Z, Yiqiao Hu. Floating matrix dosage form for

phenoporlamine hydrochloride based on gas forming agent: In vitro and In vivo

evaluation in healthy volunteers. Int J Pharm. 310, 2006, 139-145.

133. Ravindra S Dhumal, Samitkumar T Rajmane, Sanjay T Dhumal, Atmaram P

Pawar, Design and evaluation of bilayer floating tablets of cefuroxime axetil for

bimodal release, Journal of Scientific & Industrial Research Vol. 65, October

2006, 812-816.

134. Narendra C, Srinath MS, Babu G. Optimization of Bilayer Floating Tablet

Containing Metoprolol Tartrate as a Model Drug for Gastric Retention. AAPS

Pharm Sci Tech. 7(2), 2006, 34.

135. Wieseaw Sawicki, Rafal Lunio. Tableting of floating pellets with verapamil

hydrochloride: influence of type of tablet press, Acta Poloniae Pharmaceutica -

Drug Research, Vol. 67 No. 1, 2010, 103-106.

239 References

136. A. Streubel, J. Siepmann and R. Bodmeier. Floating matrix tablets based on low

density foam powder: effects of formulation and processing parameters on drug

release, European Journal of Pharmaceutical Sciences, 18(1), 2003, 37-45.

137. Nurten Özdemir and Sefika Ordu. Improvement of Dissolution Properties of

Furosemide by Complexation with β-Cyclodextrin, Drug Development and

Industrial Pharmacy, 24(1), 1998, 19-25.

138. Nathalie Rouge, et al. Comparative pharmacokinetic study of a floating

multiple-unit capsule, a high-density multiple-unit capsule and an immediate-

release tablet containing 25 mg atenolol, Pharmaceutica Acta Helvetiae, 73(2),

1998, 81-87.

139. R.F. Weska, J.M. Moura, L.M. Batista, J. Rizzi and L.A.A. Pinto. Optimization

of deacetylation in the production of chitosan from shrimp wastes: Use of

response surface methodology, Journal of Food Engineering, 80(3), 2007, 749-

753.

140. Harpreet K. Dhiman, Alok R. Ray and Amulya K. Panda. Characterization and

evaluation of chitosan matrix for In vitro growth of MCF-7 breast cancer cell

lines, Biomaterials, 25(21), 2004, 5147-5154 .

141. Rinaudo, M. Chitin and chitosan: Properties and applications, Progress in

Polymer Science, 31(7), 2006, 603-632.

142. V. R. Sinha , A. K. Singla , S. Wadhawan , R. Kaushik , R. Kumria , K. Bansal

and S. Dhawan. Chitosan microspheres as a potential carrier for drugs,

International Journal of Pharmaceutics, 274(1-2), 2004, 1-33.

143. Radi Hejazi and Mansoor Amiji. Chitosan-based gastrointestinal delivery

systems, Journal of Controlled Release, 89(2), 2003, 151-165.

240 References

144. Picker-Freyer KM, Brink D. Evaluation of Powder and Tableting Properties of

Chitosan. AAPS PharmSciTech. 7(3), 2006, 75.

145. Entsar S. Abdou, Khaled S.A. Nagy and Maher Z. Elsabee. Extraction and

characterization of chitin and chitosan from local sources, Bioresource

Technology, 99(5), 2008, 1359-1367.

146. Alaa Eldeen B. Yassin, Ibrahim A. Alsarra and Abdulah M. Al-Mohizea,

Chitosan Beads as a New Gastroretentive System of Verapamil, Sci Pharm. 74,

2006, 175–188.

147. I. C. E. Wesdorp, W. Dekker and H. P. M. Festen. Efficacy of famotidine 20 mg

twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative

reflux esophagitis, Digestive Diseases and Sciences, 38(12), 2005, 2287-2293.

148. Ranitidine hydrochloride tablets, USP 150 mg and 300 mg, Available at:

http://www.medicineonline.com/drugs/R/3479/RANITIDINE-TABLETS-

USP.html [Accessed October 2008].

149. A. M. Umarunnisha, S. Palanichamy, M. Rajesh, S. Jeganath, A.

Thangathirupathi. Formulation and evaluation of matrix tablets of Famotidine

using hydrophilic polymer, Archives of Applied Science Research, 2(3), 2010,

212-220.

150. Yu-meng Wei and Ling Zhao. In vitro and In vivo evaluation of ranitidine

hydrochloride loaded hollow microspheres in rabbits, Archives of Pharmacal

Research, 31(10), 2008, 1369-1377.

151. Mohamed HG Dehghan Furquan N Khan. Gastroretentive Drug Delivery

Systems: A Patent Perspective, International Journal of Health Research, 2(1),

2009, 23-44.

241 References

152. Radi Hejazi and Mansoor Amiji. Chitosan-based gastrointestinal delivery

systems, Journal of Controlled Release, 89(2), 2003, 151-165.

153. J. Shaji, V. Jain, S. Lodha. Chitosan: A Novel Pharmaceutical Excipient,

International Journal of Pharmaceutical and Applied Sciences, 1 (1), 2010, 11-

28.

154. Qi Zhao Wanga, et al. Protonation constants of chitosan with different

molecular weight and degree of deacetylation, Carbohydrate Polymers, 65(2),

2006, 194-201.

155. Mao S, Shuai X, Unger F, Simon M, Bi D, Kissel T, The depolymerization of

chitosan: effects on physicochemical and biological properties, Int J Pharm.

281(1-2), 2004, 45-54.

156. Pradip Kumar Dutta, Joydeep Dutta, V S Tripathi. Chitin and chitosan:

Chemistry, properties and applications, Journal of Scientific & Industrial

Research 63, 2004, 20-31.

157. F.A. Al Sagheera, M.A. Al-Sughayerb, S. Muslima, M.Z. Elsabee. Extraction

and characterization of chitin and chitosan from marine sources in Arabian Gulf,

Carbohydrate Polymers. 77(2), 2009, 410-419.

158. Xuan Jiang, Lirong Chen, Wei Zhong. A new linear potentiometric titration

method for the determination of deacetylation degree of chitosan, Carbohydrate

Polymers. 54(4), 2003, 457-463.

159. Harpreet K. Dhiman, Alok R. Raya, Amulya K. Panda. Characterization and

evaluation of chitosan matrix for In vitro growth of MCF-7 breast cancer cell

lines, Biomaterials. 25(21), September 2004, 5147-5154.

160. Indian Pharmacopoeia. The Controller of Publication. Delhi, 2, 1996, 735.

242 References

161. Qing Sheng Zhao et al. Preparation of alginate coated chitosan hydrogel beads

by thermosensitive internal gelation technique. Journal of Sol-Gel Science and

Technology. 54(2), 2010, 232-237.

162. Reddy NR, Prabhavathi K, Bhaskar Reddy YV, Chakravarthy IE. A new

spectrophotometric determination of famotidine from tablets. Indian J Pharm Sci

68, 2006, 645-647.

163. Trivedi, N.D., U.N. Trivedi, M.M. Patel, J.K. Patel and A. Bhandari. Preparation

and evaluation of floating matrix tablet of ranitidine. Am. J. Drug Discovery

Develop. 1, 2011, 8-23.

164. P. Narayana Raju, K. Prakash, M. Lakshmi Narasu. Compatibility Study of

Lamivudine with Various Cellulose Polymers, E-Journal of Chemistry, 6(S1),

2009, S17-S20.

165. B.Mandal, K. S.Alexander, A. T.Riga. Evaluation of the drug-polymer

interaction in calcium alginate beads containing diflunisal. 65(2), 2010, 106-

109.

166. G. Bruni, L. Amici, V. Berbenni, A. Marini, A. Orlandi. Drug-Excipient

Compatibility Studies. Search of interaction indicators, Journal of Thermal

Analysis and Calorimetry. 68(2), 2004, 561-573.

167. S. T. Prajapati, L. D. Patel, D. M. Patel. Studies on Formulation and In vitro

Evaluation of Floating Matrix Tablets of Domperidone. Indian J Pharm Sci.

71(1), 2009, 19–23.

168. Anilkumar J. Shinde , Manojkumar S. Patil, Harinath N. More. Formulation and

Evaluation of an Oral Floating Tablet of Cephalexin. Indian J.Pharm. Educ. Res.

44(3), 2010, 243-252.

243 References

169. Sanjay S. Patel, S. Ray, R. S. Thakur. Formulation and evaluation of floating

drug delivery system containing clarithromycin for helicobacter pylori, Acta

Poloniae Pharmaceutica - Drug Research, 63(1), 2006, 53-61.

170. Havaldar VD, Kulkarni AS, Dias RJ, Aloorkar NH, Mali KK. Floating matrix

tablets of atenolol: Formulation and In vitro evaluation. Asian J Pharm, 3, 2009,

286-291.

171. Ravi Kumar, M. B. Patil, Sachin R. Patil, Mahesh S. Paschapur. Formulation

and Evaluation of Effervescent Floating Tablet of Famotidine, International

Journal of PharmTech Research, 1(3), 2009, 754-763.

172. Mukesh C. Gohel, Pavak R. Mehta, Rikita K. Dave, Nehal H. Bariya. A More

Relevant Dissolution Method for Evaluation of Floating Drug Delivery System,

Dissolution technologies, 2004, 22-25.

173. Ritger PL, Peppas NA. A simple equation for the description of solute release,

II: Fickian and anomalous release from swellable devices. J Control Release. 5,

1987, 37-42.

174. M. Harris Shoaib, Jaweria Tazeen, Hamid A. Merchant, Rabia Ismail Yousuf.

Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC,

Pak. J. Pharm. Sci., 19(2), 2006, 119-124.

175. Carstensen, J.T. "Stability and Dating of Solid Dosage Forms," Pharmaceutics

of Solids and Solid Dosage Forms, Wiley-Interscience, 1977, 182-185.

176. Hsin-ya Lee, Pao-chu Wu, Yung-jin Lee, Stab: An R package for drug stability

data analysis, 100(2), 2010, 140-148.

177. Q1E Evaluation of Stability Data, Guidance for Industry, ICH June 2004, 1-11.

178. Shah SS, Pandya SJ, Waghulade MK. Development and investigation of gastro

retentive dosage form of weakly basic drug. Asian J Pharm, 4, 2010, 11-6.

244 References

179. Baumgartner S., Julijana K., Franc V., Polona V. and Bojon J. Optimization of

floating matrix tablets and evaluation of their gastric residence time, Int. J.

Pharm., 195, 2000, 125-135.

180. Koresmeyer R W, Gurny R, Doelkar E, Buri P, Peppas N A. Mechanisms of sol

ute release from porous hydrophilic polymer. Int J Pharm 15, 1983, 23‐25.

181. N. Helali, F. Darghouth and L. Monser. RP-HPLC Determination of Famotidine

and its Potential Impurities in Pharmaceuticals, 60(7-8), 2004, 455-460.

182. T C Dowling, R F Frye. Determination of famotidine in human plasma and urine

by high-performance liquid chromatography, J Chromatogr B Biomed Sci Appl.

732(1), 1999, 239-243.

183. Salem, M. S., Gharaibeh, A. M., Alkaysi, H. N. and Badwan, A. High-

Performance Liquid Chromatographic analysis of ranitidine in plasma and urine.

Journal of Clinical Pharmacy and Therapeutics, 13, 1988, 351–357.

184. V. Das Gupta. Quantitation of Ranitidine Hydrochloride in Tablets and

Injections Using High-Performance Liquid Chromatography, Drug

Development and Industrial Pharmacy - 14(12), 1998, 1647-1655.

185. D. Harries., H. L. Sharma. GI transit of potential bioadhesive formulations in

man: A scintigraphic study. J. Control. Release, 12, 1990, 45-53.

186. J. Timmermans, V. B. Gansbeke, A. J. Moes. Assessing by gamma scintigraphy

the In vivo buoyancy of dosage forms having known size and floating force

profiles as a function of time. Vol I. Proceedings of the 5th International

Conference on Pharmacy Technology. Paris, France: APGI, 1989: 42-51.

187. V F Smolen. Bioavailability and Pharmacokinetic Analysis of Drug Responding

Systems, Annual Review of Pharmacology and Toxicology, 18, 1978, 495-522.

245 References

188. Ylitalo, P., Hinkka, H, Neuvonen, P.J. Effect of exercise on the serum level and

urinary excretion of tetracycline, doxycyclineand sulphamethizole. Eur. J. din.

Pharmac, 12, 1977, 367-373.

189. Sajid Bashir, Mohammad Jamshaid, Bashir Ahmad, Javeid Iqbal,

Pharmacokinetics of ciprofloxacin in normal rabbits and changes observed in

induced dehydrated state, Pak. J. Pharm. Sci., 21(3), 2008, 225-229.

190. Oncology Tools: Dose Calculator, US Food and Drug Administration, Available

online at http://www.accessdata.fda.gov/scripts/cder/onctools/animalquery.cfm

[Accessed on: 14/04/2008].

191. Blood collection and administration of fluids and drugs (rabbit), Available

online at http://research.uiowa.edu/animal/?get=rbt_tech [Accessed on:

04/04/2008].

192. Seham A. Elkheshen, Alaa Eldeen, B. Yassin, Saleh Alsuwayeh, Fayza A.

Alkhaled. In vitro and In vivo evaluation of Floating controlled release dosage

forms of verapamil hydrochloride, Pharm. Ind. 66, Nr. 11, 2004, 1064-1372.

193. Guidance for Industry, Statistical approaches to establishing bioequivalence, US

FDA, Center for drug evaluation and research, 2001, 1-45.

194. Hsin-ya Lee and Yung-jin Lee, Bear: The data analysis tool for average

bioequivalence (ABE) and bioavailability (BA) in R Available online at

http://pkpd.kmu.edu.tw/bear/ [Accessed on: 15/07/2010].

195. Nattee Sirisuth, Natalie D. Eddington. In vitro-In vivo Correlation Definitions

and Regulatory Guidance, International Journal of Generic Drugs, Available

online at http://www.locumusa.com [Accessed on: 07/06/2009].

196. Jaber Emami, In vitro - In vivo Correlation: From Theory to Applications, J

Pharm Pharmaceut Sci 9(2), 2006, 169-189.

246 References

197. Hsin-ya Lee and Yung-jin Lee, IVIVC for R - A Tool for ―In vitro-In vivo

Correlation" Exploration with R Available at http://pkpd.kmu.edu.tw/ivivc/

[Accessed on: 15/07/2010].

198. Selye, H. A Syndrome produced by diverse nocuous agents. Nature 138, 1936,

32.

199. Hanson, H.M, Brodie, D.A. Use of the restrained rat technique for study of the

antiulcer effect of drugs, J. Appl. Physiol, 15, 1960, 291-294.

200. Chun-Chao Chang, Sheng-Hsuan Chen, Gi-Shih Lien, Horng-Yuan Lou, Ching-

Ruey Hsieh, Chia-Lang Fang, Shiann Pan. Eradication of Helicobacter pylori

significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-

treated Mongolian gerbils, World J Gastroenterol, 11(1), 2005, 104-108.

201. Piper DW, Stiel DD. Pathogenesis of chronic peptic ulcer DW, Stiel DD.

Pathogenesis of chronic peptic ulcer, current thinking and clinical implications.

Med Prog 2, 1986, 7-10.